Opin vísindi

Fletta eftir höfundi "Pombo-Suarez, Manuel"

Fletta eftir höfundi "Pombo-Suarez, Manuel"

Röðun: Raða: Niðurstöður:

  • Icon
    Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 
    Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)
    OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
  • Icon
    Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration 
    Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, Manuel; Sanchez-Piedra, Carlos; Eklund, Kari; Relas, Heikki; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Jones, Gareth T.; Codreanu, Catalin; Ionescu, Ruxandra; Nekvindova, Lucie; Závada, Jakub; Atas, Nuh; Yolbas, Servet; Fagerli, Karen Minde; Michelsen, Brigitte; Rotar, Ziga; Tomšič, Matija; Iannone, Florenzo; Santos, Maria Jose; Avila-Ribeiro, Pedro; Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jacobsson, Lennart T.H.; Askling, Johan; Nissen, Michael J. (2021-06-03)
    Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains ...
  • Icon
    Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries 
    Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Guðbjörnsson, Björn; Codreanu, Catalin; Yilmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Möller, Burkhard; Favalli, Ennio G.; Sánchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Löve, Þorvarður Jón; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; van der Horst-Bruinsma, Irene; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Hetland, Merete L. (2022-04-29)
    Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the ...